Skip to main content
Premium Trial:

Request an Annual Quote

Nicholas Naclerio, Tom Willis, Mostofa Ronaghi, Kim Blickenstaff, Jacqueline Barton

Premium

Nicholas Naclerio has been appointed president of ParAllele BioScience, the company said last week. Naclerio comes to the South San Francisco genotyping company from a stint as an independent consultant for life sciences and venture capital companies. Before that, he was chief business officer of protein chip company Zyomyx between November 2001 and early 2002. Previously, Naclerio was an executive at Motorola, where he founded the company’s life sciences business unit and led the launch of its CodeLink microarray platform between the late 1990s and 2001. He was an assistant director at the US government’s Defense Advanced Research Projects Agency before joining Motorola. Naclerio has also served on the boards of Orchid BioScience, Genometrix, the SNP Consortium, and Clinical Microsensors, which Motorola acquired in 2000. Tom Willis, Par-Allele’s current president, has been appointed chief scientific officer. Mostofa Ronaghi, a co-founder of the company, will leave the board of directors, and will join the company’s scientific advisory board.



Kim Blickenstaff joins the board of directors of GeneOhm Sciences, a San Diego-based company commercializing a biochip-based diagnostic technology invented by Jacqueline Barton of the California Institute of Technology. Blickenstaff is co-founder, president, and chief executive officer of Biosite.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.